west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "Myocardial protection" 20 results
  • Application of Systemic-Normothermic/Cardiac-hypothermic Cardiopulmonary Bypass on Surgery of Congenital Heart Disease

    Objective To investigate the value of systemic-normothermic/cardiac-hypothermic cardiopulmonary bypass(CPB)on operation of congenital heart disease. Methods Thirty patients of congenital heart disease were randomly divided into two groups, the normothermia group(n=15)and hypothermia group(n=15). The changes of CPB time, aortic cross-clamp time,operation time and postoperative drainage and the value of blood cell were observed. Results The duration of CPB (37. 5 ±11. 6rain vs. 51. 6± 12. 0 min, P〈0. 05) and operation time (2.2± 0.6h vs. 2. 7±0. 5h, P〈0. 01) in normothermia group were shorter than those of hypothermia group statistically, the differences of postoperative drainage and the value of blood cells between two groups were not statistically significant. Conclusion The use of systemic-normothermic/cardiac-hypothermic CPB on operation of congenital heart disease shows that the time of operation is shorter remarkly , and it could be clinically used safely.

    Release date:2016-08-30 06:18 Export PDF Favorites Scan
  • Donor Heart Procurement of Heart Transplantation on 61 Patients

    Objective To summarize the experiences of donor heart procurement of heart transplantation so as to improve the efficiency of donor heart protection. [WTHZ]Methods [WTBZ]From April 2002 to October 2006, sixtyone patients with endstage heart disease had undergone orthotopic heart transplantation. Donors were all male brain deaths, aged from 21 to 53, and 5 of them were older than 40. There were 6 cases in which the weight difference between donor and recipient>20%, and the rest ≤±20%. Fortyfive cases had the same ABO blood type, and 16 had matching ABO blood type. Four donor hearts were procured under the condition of stable hemodynamics and enough oxygen after brain death(typeⅠ), fortyfour donor hearts were procured under the condition of brain death with acute hemorrhage and hypovolemia (typeⅡ), and 13 donor hearts were procured under the condition of brain death with cardiac arrest (typeⅢ). Twenty cases underwent standard transplantation procedure, one underwent total heart transplantation procedure and 40 underwent bicaval transplantation procedure. The donor heart cold ischemic period ranged from 52 to 347 min(92±31 min), and 13 cases were more than 240 min. Results Two cases died of low cardiac output syndrome on 7th and 9th day after operation respectively, and their donor heart cold ischemic period were 327 and 293 min respectively. The rest of patients all recovered and discharged. One died of acute rejection on 18th month after operation because of rejecting immunosuppressive agents, and 1 died in traffic accident on 23rd month after transplantation. The rest 57 cases survived 6-59 months(mean 35 months), and had good life quality with NYHA cardiac function classification in 0-I grade. Conclusions Heart transplantation with donor aged over 40 may also have satisfactory results. Patients with endstage dilated cardiomyopathy can procure donor heartsfrom donors with heavy weight. Using different techniques to procure donor hearts may furthest reduce myocardial injury. Donor hearts which have been protected by myocardium protecting liquid for a long time should be used with caution.

    Release date:2016-08-30 06:06 Export PDF Favorites Scan
  • Progress in Ischemic Postconditioning: A Review

    Abstract: Ischemia postconditioning is a new concept based on ischemic preconditioning. It has become a hot topic in protection of ischemic-reperfusion injury because of its effective protection, relative ease of application, and postconditioning. However, its precise mechanisms and most effective application methods are still unclear. This review covers recent progress in the understanding, developments (in remote postconditioning and pharmacological postconditioning), applications to the protection of heart, lung, liver, kidney, and brain, mechanisms and appropriate protocol of ischemic post-conditioning.

    Release date:2016-08-30 05:50 Export PDF Favorites Scan
  • Protective Effects of Diazoxide-preconditioning on Myocardial Ischemia-reperfusion Injury of Rats

    Objective To observe the protective effects of diazoxide-preconditioning on myocardial ischemiareperfusion injury of rats and discuss its possible mechanisms. Methods Fourteen healthy SD rats were randomly divided into two groups(7 each group),In diazoxide-preconditioning group diazoxide was injected with the dosage of 12.5mg/kg through the vein,and in control group the media with the same amount was only given before ischemia. The left anterior descending branch was ligated for 2 hours. The heart was quickly excised after 2 hours reperfusion to be used for measurement of the quantity of malondialdehyde(MDA), the activity of superoxide dismutase (SOD), the size of myocardial infarct area, and the cell apoptosis and ultrastructure in ischemic area. Results Compared with the control group, the quantity of MDA,the percentage of the weight of myocardial infarct area/ischemic area, and the rate of cell apoptosis in the diazoxide-preconditioning group were greatly reduced (P〈0.05, 0. 01). The damage of cell uhrastructure was obviously alleviated,Conclusion Diazoxide-preconditioning provides evident cardioprotective effect on the myocardial ischemia-reperfusion injury of rats.

    Release date:2016-08-30 06:26 Export PDF Favorites Scan
  • Application of Del Nido cardioplegia in adult valve surgery: A case control study

    Objective To investigate the myocardial protective effects of Del Nido cardioplegia and analyze its advantages in adult cardiac surgery. Methods We retrospectively analyzed the clinical data of 96 adult patients undergoing cardiac valve surgery who received Del Nido cardioplegia (a DNC group) from June 2016 to January 2017 in our hospital. There were 44 males and 52 females with a mean age of 51.36±13.31 years. Meanwhile 96 patients who received conventional cardioplegia were recruited as a control group (a CTC group) and there were 53 males and 43 females with a mean age of 52.91±10.95 years. Cross-clamping time, cardiopulmonary bypass (CPB) time, total volume of and transfusion frequency of cardioplegia, the rate of spontaneous defibrillation, red blood cell transfusion and vasoactive-inotropic score at postoperative 24 hours (VIS 24) were recorded. Results No significant difference was found in age, body weight, ejection fraction, hematokrit, CPB time and cross-clamping time between the DNC group and CTC group. There was no significant difference in the rate of spontaneous defibrillation, VIS 24, cardiac enzymes and cardiactroponin I and length of ICU stay between the two groups. The total volume and transfusion frequency of cardioplegia, perioperative blood transfusion were lower in the DNC group. There was no new atrial fibrillation or in-hospital death in the two groups. Conclusion Del Nido is a good myocardial protection solution in adult cardiac valve surgery, and requires less static preload volume and reduceshemodilution and perioperative blood transfusion.

    Release date:2018-08-28 02:21 Export PDF Favorites Scan
  • Efficacy of Tight Heart Rate Control for Perioperative Myocardial Protection: A Systematic Review

    Objective To systematically review the influence of tight heart rate (HR) control on the efficacy of perioperative β-blockade, and discuss the effective measures of perioperative myocardial protection. Methods We searched the PubMed, OVID, EMbase, the Cochrane Library and Chinese Biomedical Database (CBM) for randomized controlled trials on evaluating perioperative β-blockers after noncardiac surgery. The quality of the included studies was evaluated by the method recommended by the Cochrane Collaboration. Meta-analyses was conducted by using the Cochrane Collaboration’s RevMan software. Results Thirteen RCTs including 11 590 patients were included. The combined results of all studies showed cardioprotective effect of β-blockers (OR=0.64, 95%CI 0.50 to 0.80, P=0.000 1), with considerable heterogeneity among the studies (I2=57%). However, grouping the trials on the basis of maximal HR showed that trials where the estimated maximal HR was 100 bpm were associated with cardioprotection (OR=0.37, 95%CI 0.26 to 0.52, Plt;0.000 01) whereas trials where the estimated maximal HR was 100 bpm did not demonstrate cardioprotection (OR=1.13, 95%CI 0.81 to 1.59, P=0.48) with no heterogeneity (I2=0%). Conclusion The evidence suggests that effective control of HR is important for achieving cardioprotection and that administration of β-blockers does not reliably decrease HRs in all patients. Judicious use of combination therapy with other drugs may be necessary to achieve effective postoperative control of HR.

    Release date:2016-09-07 11:04 Export PDF Favorites Scan
  • Myocardial Protection of Sevoflurane Used in the Whole Process of Cardiopulmonary Bypass:A RandomizControlled Trial HU Qiang,GAO Guo-dong,YU Kun,JIANG Fu-qing,LONG Cun.

    Abstract: Objective To observe myocardial protective effect of sevoflurane used in the whole process of cardiopulmonary bypass(CPB). Methods A total of 150 patients older than 18 years who underwent cardiac surgery under CPB in Fu wai Hospital from January 2010 to November 2011 were enrolled in this double-blind and randomized controlled study. All the patients were randomly divided into three groups:Sevoflurane pretreatment group (Group A,n=50),whole-process Sevoflurane group (Group B,n=50),and whole-process intravenous anesthesia group (Group C,n=50). Radial artery pressure and other hemodynamic parameters were continuously measured for all the patients. At following time points: CPB beginning (T1),aortic declamping (T2),3 hours after aortic declamping (T3),and 24 hours after aortic declamping (T4),serum concentrations of cardiac troponin I (cTnI) and other parameters were measured by enzyme-linked immunosorbent assay (ELISA). Results There were 31 males and 19 females at age of 60.43±3.24 years in group A,28 males and 22 females at age of 59.88±4.12 years in group B,31 males and 19 females at age of 58.76±3.87 years. There was no statistical difference in mean arterial pressure (MAP),central venous pressure (CVP),pulmonary artery wedge pressure (PAWP) and heart rate (HR) at respective time points among the 3 groups (P>0.05). At T1 and T2,there was no statistical difference in cardiac index (CI) among the 3 groups (P>0.05). At T3,there was no statistical difference in CI between Group A and Group C(F=3.382,P=0.845),but CI of Group B was significantly higher than that of Group A and C(F=3.382,3.382; P=0.033,0.020). At T4,CI of Group B was significantly higher than that of Group A and C (F=13.324,13.324; P=0.005,P=0.000),and CI of Group A was significantly higher than that of Group C (F=13.324,P=0.024). At T1 and T2,there was no statistical difference in serum concentrations of creatinine kinase MB (CK-MB),cTnI,interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) among the 3 groups (P>0.05). At T3 and T4,serum concentrations of CK-MB,TNF-α,IL-6 and cTnI of Group C were significantly higher than those of Group A,and serum concentrations of CK-MB,TNF-α,IL-6 and cTnI of Group A were significantly higher than those of Group B (F=531.616,5.410,3.5813,3.160,1.126,4.702,7.819,5.424,all P=0.000). Conclusion Sevoflurane used in the whole process of CPB has definite myocardial protective effect which is ber than that of Sevoflurane pretreatment.

    Release date:2016-08-30 05:47 Export PDF Favorites Scan
  • Advances in Erythropoietin's Myocardial Protective Effects

    Erythropoietin (EPO) is known as a classical hematopoietic growth factor, which has been used to treat anemia caused by different reasons. In recent years, EPO's non-hematopoietic biological effects have gradually become a focus. Among these effects, EPO's tissue protection is most attractive and EPO has been proved to protect many different tissues and organs. Myocardial protection has always been the important and key topic in the field of cardiovascular diseases. Reports about EPO's myocardial protective effects have been published in the recent two years, which direct the research about myocardial protection with new ideas. In this article, the discoveries and unsolved problems associated with EPO's myocardial protection were reviewed.

    Release date:2016-08-30 06:18 Export PDF Favorites Scan
  • Recovery of Cardiac Function during Weaning from Cardiopulmonary Bypass

    From aortic declamping to weaning from cardiopulmonary bypass (CPB), myocardium needs recovery not only from surgical and ischemia/reperfusion injury, but also of its full performance of pumping function as quickly as possible. In the early period of resuming myocardial perfusion, coronary blood flow should be increased, but ventricular volume overload, large dosage of adrenaline and isoprenaline, and high-energy defibrillation should be avoided. Thenappropriate management according to cardiac function and ECG changes is needed for successful weaning from CPB.

    Release date: Export PDF Favorites Scan
  • Clinical Outcomes of Papaverine Perfusion under Cardiopulmonary Bypass in Coronary Artery Bypass Grafting

    ObjectiveTo explore clinical outcomes of papaverine via the aortic root under cardiopulmonary bypass (CPB) in coronary artery bypass grafting. MethodsA total of 263 patients with coronary artery disease underwent CPB in coronary artery bypass grafting in Beijing Anzhen Hospital from August 2003 through December 2014 were included. According to whether or not they received papaverine perfusion via the aortic root in the first perfusion during CPB, all the 263 patients were divided into two groups including an intervention group and a control group. There were 176 patients in the intervention group including 109 males and 67 females with their average age of 64.37±23.54 years. They received aortic root perfusion of 60 mg papaverine diluted into 20 ml during the first perfusion, and repeated aspiration was performed 8 to 10 times in CPB when the heart beat weak. In the control group, there were 87 patients including 55 males and 32 females with their average age of 65.98±29.13 years. Patients in the control group received routine procedures of CPB except papaerine perfusion. Clinical effectiveness was compared between the two groups. ResultsThere was no in-hospital death. CPB supporting time after heart re-beating (9.58±3.21 min vs. 19.74±5.67 min, t=-1.133, P=0.000), dopamine usage 3.12±1.27 μg/(kg·min) vs. 4.98±2.53 μg/(kg·min),t=-0.913, P=0.031), epinephrine usage 0.018±0.009 μg/(kg·min) vs. 0.047±0.011 μg/(kg·min), t=-0.811, P=0.018) and nor epinephrine usage 0.021±0.011 μg/(kg·min) vs. 0.037±0.010 μg/(kg·min), t=-0.823, P=0.019) of the intervention group were significantly shorter or lower than those of the control group. Automatic heart re-beating rate of the intervention group was significantly higher than that of the control group (98.86% vs. 70.11%,t=-1.372, P=0.000). A total of 176 patients in the nitroglycerin group were followed up for 6-121 months, and 16 patients were lost during follow-up. During the follow-up period, 6 patients were hospitalized for cardiac events, and 2 died in 29 months and 103 months after surgery, and 9 died from cardiac events. ConclusionFor the patients undergoing on-pump coronary artery bypass grafting, some myocardial protection strategies including papaverine perfusion via the aortic root in the first perfusion, use of norepinephrine, and aortic root squeezing in high frequency by hand can significantly increase the automatic heart re-beating rate, shorten the CPB supporting time after heart re-beating, and improve postoperative clinical outcomes.

    Release date:2016-12-06 05:27 Export PDF Favorites Scan
2 pages Previous 1 2 Next

Format

Content